Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976476 · ClinicalTrials.gov registry record · Phase 2
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
A Phase 2 study of Multiple Myeloma and Hypogammaglobulinemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT06976476: Recruiting Phase 2 study of Multiple Myeloma and Hypogammaglobulinemia, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06976476 is a Phase 2 study of Multiple Myeloma and Hypogammaglobulinemia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06976476, a Phase 2 study of Multiple Myeloma and Hypogammaglobulinemia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
Primary Outcome
To compare overall infection rates amongst (RR) multiple myeloma patients with hypogammaglobulinemia receiving subcutaneous immunoglobulin (IgPro20) to those in observational arm over a 6-month period.
Conditions Studied
Interventions
- DRUG IgPro20
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Mount Sinai Hospital - New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2029-05-08 |
| Phase | Phase 2 |
What NCT06976476 shows while recruiting
NCT06976476 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which IgPro20 is the first listed.
NCT06976476 lists 8 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06976476 about?
NCT06976476 is a clinical study titled "Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia". The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
What is the current status of trial NCT06976476?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-05-08. Estimated completion is 2029-05-08.
What conditions does trial NCT06976476 study?
This clinical trial studies the following conditions: Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired.
What interventions are being tested in trial NCT06976476?
The interventions under investigation include: IgPro20 (DRUG).
Who is sponsoring clinical trial NCT06976476?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06976476 being conducted?
This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06976476's enrollment target sits among peer trials
100 165th of 438 higher than 262 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI